Article: Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter? Journal: International Journal of Technology Management (IJTM) 2019 Vol.80 No.3/4 pp.177 - 211 Abstract: The paper deals with the determinants of worldwide IP coverage of patented inventions in large pharmaceutical firms. We support the core idea that the internationalisation of firm R&D and an economic presence in a foreign country are positive key factors which explain global IP coverage. For the global pharmaceutical industry, we estimate probit models on the probability that a patent will be expanded worldwide. We retain two categories of worldwide patent: the well-known triadic patent and the new triadic one (triadic + China + Korea). The data set encompasses the 17,633 priority patents applied for by 76 enterprises from several countries over the period 2003-2005. One important finding is that patenting in Japan sets up an important barrier, giving Japanese firms an advantage when triadic patenting is considered. For European and US firms, our estimation results confirm the idea that the level of firm R&D internationalisation is a significant explanatory factor in international IP coverage, together with control variables. We highlight an inverted U-shaped relationship between these two variables. The hypothesis related to a firm economic presence is also verified. Inderscience Publishers - linking academia, business and industry through research

Title: Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter?

Authors: Patricia Laurens; Christian Le Bas; Antoine Schoen

Addresses: Université Paris Est, 2, bd Blaise Pascal, 93160 Noisy le Grand, France; Scientific Research National Center (CNRS), 3 Rue Michel Ange, 75016 Paris, France; Interdisciplinary Laboratory Science Innovations Society (LISIS), 5 Boulevard Descartes, 77420 Champs-sur-Marne, France; Institute for Research and Innovation in Society (IFRIS), 113 Rue Marietton, 69009 Lyon, France ' ESDES – Business School of UCLy, 10, Place des Archives, 69002 Lyon, France ' Université Paris Est, 2, bd Blaise Pascal, 93160 Noisy le Grand, France; Institute for Research and Innovation in Society (IFRIS), 113 Rue Marietton, 69009 Lyon, France; Interdisciplinary Laboratory Science Innovations Society (LISIS), 5 Boulevard Descartes, 77420 Champs-sur-Marne, France; ESIEE Paris, Cité Descartes, 2 Boulevard Blaise Pascal, 93160 Noisy-le-Grand, France

Abstract: The paper deals with the determinants of worldwide IP coverage of patented inventions in large pharmaceutical firms. We support the core idea that the internationalisation of firm R&D and an economic presence in a foreign country are positive key factors which explain global IP coverage. For the global pharmaceutical industry, we estimate probit models on the probability that a patent will be expanded worldwide. We retain two categories of worldwide patent: the well-known triadic patent and the new triadic one (triadic + China + Korea). The data set encompasses the 17,633 priority patents applied for by 76 enterprises from several countries over the period 2003-2005. One important finding is that patenting in Japan sets up an important barrier, giving Japanese firms an advantage when triadic patenting is considered. For European and US firms, our estimation results confirm the idea that the level of firm R&D internationalisation is a significant explanatory factor in international IP coverage, together with control variables. We highlight an inverted U-shaped relationship between these two variables. The hypothesis related to a firm economic presence is also verified.

Keywords: global patent coverage; pharma firms; internationalisation of R&D; strategy; globalisation of technology.

DOI: 10.1504/IJTM.2019.100283

International Journal of Technology Management, 2019 Vol.80 No.3/4, pp.177 - 211

Accepted: 02 Feb 2018
Published online: 24 Jun 2019 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article

Title: Worldwide IP coverage of patented inventions in large pharma firms: to what extent do the internationalisation of R&D and firm strategy matter?

Keep up-to-date